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ABSTRACT 
 
Obesity is associated with elevated levels of serum fatty acids, which accumulate in non-
adipose tissues including the liver. Elongation factor 1A-1 (EF1A-1) has previously been 
shown to participate in the cell stress and death response of cardiomyocytes to excess 
saturated fatty exposure, and in steatotic mouse myocardium. In this thesis, the hypothesis that 
the hepatocyte response to fatty acid overload involves EF1A-1 was tested. EF1A-1 
expression was induced in the livers of obese mice in association with severe hepatic steatosis, 
and in HepG2 human hepatoma cells in response to excess palmitate. Partial translocation of 
EF1A-1 from the ER to polymerized actin preceded palmitate-induced cell death. Inhibiting 
the elongation function of the protein using a specific inhibitor decreased palmitate-induced 
cell death. Results indicate EF1A-1 participates in hepatocyte stress response to saturated fatty 
acid excess possibly by mediating changes in protein synthesis related to actin cytoskeleton 
remodeling that occur during cell stress. 
 
 
 
 
 
 
 
Keywords: Elongation factor 1A-1, obesity, NAFLD, lipotoxicity, hepatic steatosis 
 
	  	   iii	  
CO-AUTHORSHIP STATEMENT 
 
Plasma and liver lipid measurements in Table 3.1 were performed through the Metabolic 
Phenotyping Laboratory in Robarts Research Institute by Cindy Sawyez and Brian Sutherland 
 
Immunofluorescence confocal images in Figures 3.7 A-F and 3.8 A-F were taken by Debra 
Robson 
 
Subcellular fractionation and immunoblotting in Figure 3.7 H was done by Dr. Nica 
Borradaile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   iv	  
ACKNOWLEDGEMENTS 
I would like to sincerely thank my supervisor Dr. Nica Borradaile for giving me the 
wonderful opportunity to be the first student to enter the lab.  Thank you for your constant 
guidance, support and patience over the last few years. No words can express my appreciation 
for everything you’ve done for me. I could not have asked for a better mentor. Thank you to 
the members of my advisory committee, Drs. Stan Leung, John Di Guglielmo and Dan Hardy 
for your guidance and insightful suggestions, and for helping me with the preparation of this 
thesis. To Debbie Robson for sharing your knowledge and expertise with me, and to Dr. 
Fabiana Caetano for teaching me about confocal microscopy. I would like to share my 
appreciation for the help of Alexandra Hetherington who assisted with several aspects of this 
project. I also would like to thank the other students in our lab, Jen Hughes-Large and 
Dominic Pang, as well as the Urquhart lab members for making the lab such a fun and friendly 
environment to work in. A special thank you goes to Tom Velenosi. You’ve helped me with 
everything and have been such a great friend. I wouldn’t have made it through grad school 
without you.   
Lastly, I would like to thank my friends and family for supporting me throughout the 
entirety of my studies. I will never forget the extraordinary opportunities graduate school has 
given me as I take the knowledge obtained and lessons learned from this chapter of my life 
into the next.   
Tissue and plasma samples from C57BL/6J and ob/ob mice were kindly provided by 
Dr. Murray Huff and former members of the Huff laboratory, Dr. Erin Mulvihill and Julia 
Assini, MSc.  
	  	   v	  
TABLE OF CONTENTS 
ABSTRACT .............................................................................................................................. ii 
CO-AUTHORSHIP STATEMENT ....................................................................................... iii 
ACKNOWLEDGEMENTS ..................................................................................................... iv 
TABLE OF CONTENTS .......................................................................................................... v 
LIST OF FIGURES ............................................................................................................... viii 
LIST OF TABLES ..................................................................................................................... x 
ABBREVIATIONS AND SYMBOLS .................................................................................... xi 
1.0 INTRODUCTION ............................................................................................................... 1 
1.1 Obesity ............................................................................................................................................ 2 
1.2 NAFLD ........................................................................................................................................... 5 
1.3 Lipotoxicity in Hepatocytes ............................................................................................................ 7 
1.3.1 Saturated and Unsaturated Fatty Acids .................................................................................. 8 
1.3.2 ER Stress ................................................................................................................................ 10 
1.3.3 Oxidative Stress ..................................................................................................................... 12 
1.3.4 Mitochondrial Dysfunction .................................................................................................... 13 
1.4 Eukaryotic elongation factor 1A-1 ................................................................................................ 16 
1.4.1 Canonical role of eEF1A-1 .................................................................................................... 16 
1.4.2 Association with the Cytoskeleton ......................................................................................... 18 
1.4.3 Role in Apoptosis ................................................................................................................... 19 
1.5 Objectives and Hypothesis ............................................................................................................ 20 
2.0 MATERIALS AND METHODS ...................................................................................... 22 
	  	   vi	  
2.1 Mice .............................................................................................................................................. 23 
2.2 Cell Culture ................................................................................................................................... 24 
2.3 Immunoblot Analyses ................................................................................................................... 25 
2.4 Cell Death ..................................................................................................................................... 26 
2.5 Immunofluorescence Confocal Microscopy ................................................................................. 27 
2.6 Subcellular Fractionation .............................................................................................................. 28 
2.7 [3H] Leucine Incorporation Assay ................................................................................................ 28 
2.8 MTT Assay ................................................................................................................................... 29 
2.9 Transfections ................................................................................................................................. 30 
2.10 Statistical analysis ....................................................................................................................... 30 
3.0 RESULTS ........................................................................................................................... 31 
3.1 eEF1A-1 and GRP78 protein are increased in the liver of some mouse models of obesity with 
hepatic steatosis ................................................................................................................................... 32 
3.2 eEF1A-1 protein is rapidly induced in response to saturated fatty acid overload-induced ER 
stress in HepG2 cells, an event that precedes cell death ..................................................................... 40 
3.3 Palmitate induces eEF1A-1 colocalization with the actin cytoskeleton ....................................... 48 
3.4 Inhibition of eEFA-1 elongation function decreases palmitate-induced cell death ...................... 53 
4.0 DISCUSSION ..................................................................................................................... 62 
4.1 Summary of Results ...................................................................................................................... 63 
4.2 eEF1A-1 in mouse models of obesity and hepatic steatosis ......................................................... 64 
4.3 eEF1A-1 as a response protein during saturated fatty acid induced ER stress and cell death ...... 64 
4.4 Subcellular localization of eEF1A-1 during fatty acid overload .................................................. 65 
4.5 Inhibition of eEF1A-1 elongation function and response to lipotoxicity ..................................... 67 
4.6 Knockdown of eEF1A-1 in hepatocytes and response to lipotoxicity .......................................... 68 
4.7 Future Directions........................................................................................................................... 71 
	  	   vii	  
5.0 REFERENCES .................................................................................................................. 73 
APPENDIX A ........................................................................................................................... 84 
CURRICULUM VITAE ......................................................................................................... 88 
 
 
 
 
 
 
 
 
  
	  	   viii	  
LIST OF FIGURES 
 
Figure 1.1 Obesity-related perturbations in metabolic control lead to ectopic lipid 
accumulation in multiple organs  ................................................................................................. 4 
Figure 1.2 Pathways involved in the cellular response to saturated fatty acid overload .......... 15 
Figure 1.3 Canonical and non-canonical functions of eEF1A-1 .............................................. 17 
Figure 3.1 eEF1A-1 and GRP78 protein are increased in some mouse models of obesity with 
hepatic steatosis ......................................................................................................................... 34 
Figure 3.2 Hepatic eEF1A-1 expression correlates with liver triglyceride content and plasma 
insulin concentration ................................................................................................................. 39 
Figure 3.3 eEF1A-1 expression is increased in HepG2 cells during fatty acid overload induced 
ER stress .................................................................................................................................... 42 
Figure 3.4 eEF1A-1 expression is increased in HepG2 cells in response to direct induction of 
oxidative or ER stress ................................................................................................................ 45 
Figure 3.5 Palmitate induces lipotoxicity in HepG2 cells ........................................................ 47 
Figure 3.6 eEF1A-1 does not colocalize with lipid droplets in HepG2 cells ........................... 50 
Figure 3.7 eEF1A-1 colocalization with the ER is decreased during exposure to excess  
palmitate .................................................................................................................................... 52 
Figure 3.8 eEF1A-1 colocalization with the actin cytoskeleton is increased during exposure to 
excess palmitate ......................................................................................................................... 55 
Figure 3.9 Inhibition of eEF1A-1 elongation function decreases palmitate-induced cell death  
 ................................................................................................................................................... 58 
	  	   ix	  
Figure 3.10 Modest long-term inhibition of eEF1A-1 expression alters HepG2 morphology    
 ................................................................................................................................................... 60 	  
Figure 4.1 Working model for the role of eEF1A-1 in hepatocyte response to saturated fatty 
excess ......................................................................................................................................... 70 
 
 
  
	  	   x	  
LIST OF TABLES 
 
Table 3.1 Parameters of metabolic disease in 3 mouse models obesity and hepatic steatosis 
 ................................................................................................................................................... 36 
 
 
  
	  	   xi	  
ABBREVIATIONS AND SYMBOLS 
 
aa-tRNA Aminoacyl-tRNA 
ALT Alanine aminotransferase 
ANOVA Analysis of variance  
AST Aspartate aminotransferase 
ATF4 Activating transcription factor 4 
ATF6 Activating transcription factor 6 
Bax Bcl-2-associated X protein  
BCA Bicinchoninic acid 
BMI Body mass index 
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate  
CD36 Cluster of differentiation 36 
cDNA Complementary DNA 
CHO Chinese hamster ovary 
CHOP C/EBP-homologous protein 
ChREBP Carbohydrate response element binding protein  
CT Computerized tomography 
CYP2E1 Cytochrome P450 2E1 
DAPI 4',6-Diamidino-2-phenylindole 
DGAT2 Diacylglycerol acyltransferase 2 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
	  	   xii	  
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
eEF1A-1 Eukaryotic elongation factor 1A-1 
eEF1B Eukaryotic elongation factor 1B 
eIF2α Eukaryotic translation initiation factor 2α 
ELISA Enzyme-linked immunosorbent assay 
EMEM Eagles minimum essential medium 
ER Endoplasmic reticulum 
F-actin Filamentous actin 
FATP Fatty acid transport protein 
FFA Free fatty acids 
FITC Fluorescein isothiocyanate 
G-actin Globular actin 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GRP78 Glucose-regulated protein 78 
GTP Guanosine triphosphate  
H2O2 Hydrogen peroxide  
HCl Hydrogen chloride 
HDL High-density lipoprotein  
HRP Horseradish peroxidase 
HSL Hormone-sensitive lipase 
IC50 Half maximal inhibitory concentration 
IRE1α Inositol-requiring enzyme 1α 
	  	   xiii	  
JNK c-jun-N-terminal kinase 
LSB Laemmli sample buffer 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADPH Nicotinamide adenine dinucleotide phosphate  
NAFLD Nonalcoholic fatty liver disease 
NaOH Sodium hydroxide 
NASH Nonalcoholic steatohepatitis  
PAGE Polyacrylamide gel electrophoresis 
PBA 4-Phenyl butyric acid 
PBS Phosphate-buffered saline 
PERK Double-stranded RNA-dependent like ER kinase 
PI Propidium iodide 
RIPA Radioimmunoprecipitation assay 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SCD1 Stearoyl-CoA desaturase  
SDS Sodium dodecyl sulfate  
SEM Standard error of mean 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SREBP-1c Sterol regulatory element-binding protein 1c 
TBS Tris-buffered saline 
	  	   xiv	  
TCA Trichloroacetic acid 
TG Triglyceride 
TGF-β Transforming growth factor β 
tRNA Transfer RNA 
UPR Unfolded protein response 
VLDL Very low-density lipoprotein 
XBP-1 X box binding protein 1 
α Alpha 
β Beta 
 
 
	  	  	  
	  
1	  
 
 
 
 
 
 
 
 
 
 
1.0 INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 	  
	  	  	  
	  
2	  
1.1 Obesity 
In recent decades, the prevalence of obesity has increased alarmingly, making it a 
significant health problem in not only high-income countries, but low and middle-income 
countries as well (World Health Organization, 2013). Obesity is defined as abnormal or 
excessive fat accumulation that presents a risk to one’s health.  A simple measurement of 
obesity is the body mass index (BMI), which is calculated by dividing a person’s weight (in 
kilograms) by the square of his or her height (in metres) (Pasco et al., 2012). A person with a 
BMI greater than 25 is considered overweight, while having a BMI greater than 30 is 
generally considered obese (Pasco et al., 2012). The primary cause of obesity is an energy 
imbalance between calories consumed and calories expended. According to statistics by The 
World Health Organization, obesity has more than doubled since 1980 and today, over 500 
million adults are obese worldwide.  In Canada, 19.8% of men and 16.8% of women over the 
age of 18 have a BMI of 30 or greater according to data collected from 2011 (Statistics 
Canada). Obesity has been recognized as an important risk factor for many other conditions 
including insulin resistance and type 2 diabetes, hypertension, dyslipidemia, coronary disease, 
heart failure, and cancer. A subset of these conditions have been clustered and described as the 
metabolic syndrome, which is an insulin-resistant state characterized by various 
cardiovascular risk factors (Johnson and Weinstock, 2006).  The current unified criteria for 
metabolic syndrome takes into account definitions from several international organizations 
(Alberti et al., 2009). These criteria are abdominal obesity (increased waist circumference) 
plus two of the following characteristics: elevated plasma triglycerides (≥1.7 mmol/l), elevated 
fasting blood glucose (≥5.6 mmol/l), decreased high-density lipoprotein (HDL) cholesterol 
(<1.03 mmol/l), and elevated blood pressure (≥130/85) (Alberti et al., 2009).  
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The majority of cells have limited ability to store excess lipids and to meet their own 
fuel needs during extended famine. As a result, specialized cells (adipocytes) have evolved to 
store fuel during caloric surplus and distribute lipids in times of need (Unger et al., 2010). 
When caloric intake exceeds caloric expenditure, adipocytes initially undergo hypertrophy. 
This process triggers adipose tissue paracrine signaling to stimulate adipogenesis in order to 
maintain adipose tissue physiological functions during increased energy storage (Bays et al., 
2008). In addition to storing excess calories as triglycerides, adipocytes secrete leptin, a 
hormone that signals satiety and reduces caloric intake. Leptin is also responsible for 
stimulating fatty acid oxidation in non-adipose tissues (Unger at al., 2010). Eventually, during 
conditions of chronic energy overload, the capacity of adipose tissue to expand and function 
fails leading to adipocyte dysfunction and uncontrolled lipolysis. This results in elevated 
circulating free fatty acids (Muoio and Newgard, 2006). In the liver, hepatocytes package and 
secrete excess lipids as very low-density lipoprotein (VLDL), however, chronic exposure of 
the liver to circulating free fatty acids (FFA) leads to hepatic insulin resistance. This impairs 
hepatic ability to downregulate VLDL production in response to insulin, resulting in VLDL 
overproduction and hypertriglyceridemia (Sparks et al., 2012). As a result of this increased 
flux of lipid from adipose and liver to peripheral tissues, fatty acids begin to accumulate in 
non-adipose locations such as the heart and cardiovascular system, skeletal muscle, kidney, 
pancreas (Brookheart et al., 2009) (Figure 1.1). Ectopic lipid accumulation can lead to insulin 
resistance in those tissues, inflammation, and apoptosis. The process leading from lipid 
accumulation to cell dysfunction and death is termed lipotoxicity, which occurs when cells can 
no longer oxidize, safely store or export excess lipid (Unger, 2003). Although dietary lipids 
are important for normal biological functions such as membrane biosynthesis, protein 
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Figure 1.1 Obesity-related perturbations in metabolic control lead to ectopic lipid 
accumulation in multiple organs.  A high calorie, high fat diet coupled with inactivity leads 
to elevated circulating free fatty acids (FA) and triglycerides (TG). During conditions of 
chronic energy overload, the capacity of adipose tissue to expand and function fails. As a 
result, lipids accumulate in non-adipose tissues such as the heart and cardiovascular system, 
skeletal muscle, kidney, pancreas and liver (indicated by yellow circles). In the liver, chronic 
exposure to excess free fatty acids impairs its ability to downregulate VLDL production, 
resulting in VLDL overproduction and hypertriglyceridemia. (Adapted from Muoio and 
Newgard, 2006) 
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modification, intracellular signaling and energy homeostasis, chronic exposure of organs to 
elevated concentrations of these lipids leads to organ dysfunction and disease development 
(Szendroedi and Roden, 2009). 
1.2 NAFLD 
Dietary intake of a high calorie and high fat diet coupled with low physical activity 
leads to increased circulating levels of free fatty acids and storage of triglycerides in ectopic 
organs, including the liver (Szendroedi and Roden, 2009). In the absence of alcohol, lipid 
accumulation within the liver is termed nonalcoholic fatty liver disease (NAFLD) and is 
considered the hepatic manifestation of the metabolic syndrome. NAFLD describes the 
chronic liver disease associated with hepatocyte lipotoxicity and is the most common form of 
liver disease affecting both adults and children throughout the world (Erickson, 2009). The 
prevalence of NAFLD is increasing due to the increasing rates of obesity, type 2 diabetes, and 
metabolic syndrome, all of which are risk factors for the development of NAFLD. It represents 
a range of hepatic disease from simple steatosis, which is the accumulation of fat in the liver 
and is considered mostly benign, to nonalcoholic steatohepatitis (NASH), characterized by 
inflammation and hepatocyte injury (Utzschneirder and Kahn, 2006). NASH can progress to 
fibrosis and cirrhosis, and ultimately end stage liver disease. As a result, NAFLD is becoming 
an increasingly common cause of liver transplantation as well as a risk factor for the 
progression of hepatocellular carcinoma, primarily due to cirrhosis associated with NAFLD 
(Shimada et al., 2002; Bullock et al., 2004).  
Most patients with fatty liver are asymptomatic and when symptoms do occur, they are 
usually non-specific. NAFLD diagnosis remains complex and is usually discovered when a 
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condition other than fatty liver is suspected (Schreuder et al., 2008). The main histological 
characteristics of NASH, in addition to steatosis, include hepatocyte ballooning, lobular 
inflammation and displacement of nuclei to the edge of the cell. The presence of fibrosis 
indicates progression of the disease to more severe liver injury (Yeh and Brunt, 2007). 
Existing non-invasive diagnostic markers of NAFLD include a set of clinical signs and 
symptoms, imaging tests and blood test results (Wieckowska and Feldstein, 2008). Elevated 
serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are primarily 
observed in patients with NAFLD. These enzymes are located within hepatocytes and are 
released into circulation upon liver injury. ALT is located predominantly in the liver, while 
AST is also found in other tissues and can be elevated in diseases affecting organs such as the 
heart or skeletal muscle (Ozer et al., 2008). However, the reliability of these tests has been 
debated due to the fact that levels fluctuate within the normal limit in the majority of patients 
with NASH (Adams and Feldstein, 2011). Common imaging techniques to diagnose hepatic 
steatosis include ultrasound, computerized tomography (CT) scan and magnetic resonance 
imaging (MRI). The most commonly used and least expensive method is ultrasound, while 
MRI is the most accurate available imaging technique for quantification of hepatic steatosis 
(Schreuder et al., 2008). Nonetheless, no imagining technique is currently capable of detecting 
the subtle histological changes, ballooning and inflammation that distinguish hepatic steatosis 
from early NASH (Adams and Feldstein, 2011). Liver biopsy remains the only reliable 
method to accurately diagnose NASH and to determine the severity of fibrosis and liver 
injury.  
The cause and progression of NAFLD is complex and not fully understood. However, 
insulin resistance is a key feature of ectopic lipid accumulation in the liver. NAFLD is linked 
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to both hepatic and adipose tissue insulin resistance in addition to a reduction in whole-body 
insulin sensitivity (Utzschneirder and Kahn, 2006). Under normal physiological conditions, 
insulin suppresses lipolysis in adipose tissue by inhibiting hormone-sensitive lipase (HSL). In 
insulin-resistant states, lipolysis is increased and esterification of fatty acids is inhibited, 
resulting in excess flux of free fatty acids to the liver (Trauner et al., 2010). The associated 
hyperinsulinemia enhances hepatic de novo lipogenesis through activation of transcription 
factors such as sterol regulatory element-binding protein 1c (SREBP-1c), which leads to the 
transcriptional activation of lipogenic genes. Furthermore, hyperglycemia induces 
carbohydrate response element binding protein (ChREBP) expression, which leads to the 
transcriptional activation of additional lipogenic genes (Trauner et al., 2010). The actions of 
these two transcription factors lead to activation of enzymes required for the conversion of 
excess glucose to fatty acids, which can be esterified into triglycerides (Trauner et al., 2010).  
Hepatic steatosis does not always progress to liver injury, indicating that other factors, 
including environmental and genetic determinants, are necessary. It is not known why some 
individuals with only hepatic steatosis progress to NASH while others do not. Some have 
suggested that the accumulation of excess triglyceride (hepatic steatosis) and lipotoxic cell 
damage are two responses that occur simultaneously, but independently (Neuschwander-Tetri, 
2010).  
1.3 Lipotoxicity in Hepatocytes 
In the early stages of NAFLD, triglycerides accumulate in hepatocytes. Serum free 
fatty acids are elevated in patients with NASH and are correlated with disease progression 
(Nehra et al., 2001). There are three main sources of hepatic lipids. Free fatty acids released 
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from adipose tissue contribute to the majority of hepatic triglyceride content and play a critical 
role in the development of NAFLD (Donnelly et al., 2005). De novo lipogenesis is the second 
most important mechanism, while dietary lipid provides about 10% of the hepatic lipid content 
(Ibrahim et al., 2011).  
Free fatty acids are carried in the circulation bound to albumin, which maintains a low 
unbound concentration and allows a higher concentration of free fatty acids to be carried in the 
serum (Bradbury, 2006).  They can enter the cell by simple diffusion, which is most likely 
when circulating, or extracellular, concentrations are very high, or by facilitated transport. 
Several fatty acid transport proteins (FATP) and the fatty acid uptake transporter CD36 have 
been identified to facilitate uptake (Pohl et al., 2004; Zhou et al, 2008). FATP5 is exclusively 
expressed in hepatocytes and is involved with uptake of long-chain (greater than 16 carbons) 
free fatty acids (Doege et al., 2006).  Once in the cell, free fatty acids may be converted to 
triglycerides or undergo β-oxidation at the mitochondria. Triglycerides may be targeted for 
export through the production of VLDL particles, or for storage in lipid droplets (Bradbury, 
2006). In hepatocytes overwhelmed by excess lipids, in particular saturated fatty acids, 
multiple lipotoxic responses are activated resulting in oxidative (Li et al., 2008; Wu et al., 
2008) and endoplasmic reticulum (ER) stress (Wei et al., 2006; Lee at al., 2010), and 
ultimately cell death.  
1.3.1 Saturated and Unsaturated Fatty Acids 
 
In recent studies, in vitro models of steatosis have been used to study the consequences 
of excess lipid accumulation in hepatocytes. These studies typically involve hepatocyte cell 
lines or primary hepatocytes treated with high pathophysiological concentrations of saturated 
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and unsaturated fatty acids conjugated to bovine serum albumin (BSA). Numerous studies 
have demonstrated that saturated fatty acids are more harmful to hepatocytes than unsaturated 
fatty acids (Wei et al., 2006; Malhi et al., 2006; Li et al., 2009). This may be due to their 
relative inefficiency, compared to unsaturated fatty acids, to be esterified and stored safely as 
triglycerides (Listenberger et al., 2003). Treating cells simultaneously with both saturated and 
unsaturated fatty acids rescues cells from saturated fatty acid induced apoptosis by diverting 
potentially toxic saturated fatty acids to triglyceride formation (de Vries et al., 2007; Akazawa 
et al., 2010).  Similar observations have been made in animal models of NAFLD suggesting 
that saturated fatty acids are damaging to the liver while unsaturated fatty acids are not (Wang 
et al., 2006; Li et al., 2009). In leptin-receptor deficient db/db mice fed a methionine and 
choline deficient diet, inhibition of diacylglycerol acyltransferase 2 (DGAT2), the enzyme 
responsible for esterification of free fatty acids into triglycerides, decreased hepatic steatosis 
but elevated hepatic free fatty acids and markers of oxidative stress, inflammation and fibrosis 
(Yamaguchi et al., 2007). Mice with hepatic DGAT2 overexpression develop hepatic steatosis 
with increased amounts of triglycerides in the liver, but no evidence of liver damage or insulin 
resistance (Monetti et al., 2007).  Genetic or pharmacological inhibition of stearoyl-CoA 
desaturase-1 (SCD1), the enzyme that converts saturated fatty acids to monounsaturated fatty 
acids, renders hepatocytes more sensitive to saturated fatty acid-induced apoptosis (Li et al., 
2009).  SCD1-/- mice fed a methionine and choline deficient diet accumulated less triglycerides 
in the liver compared to wild-type mice but have increased serum free fatty acids, hepatocyte 
apoptosis, liver damage and fibrosis. Meanwhile, mice fed a methionine and choline deficient 
diet supplemented with oleate, a monounsaturated fatty acid, have less severe liver injury and 
apoptosis (Li et al., 2009). Taken together, this suggests that saturated fatty acids are primarily 
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responsible for hepatocyte lipotoxicity, while their esterification into triglycerides serves as a 
protective mechanism.  
1.3.2 ER Stress 
 
The ER is responsible for many cellular functions such as protein synthesis, lipid 
synthesis, carbohydrate metabolism, calcium homeostasis and drug detoxification. It also 
plays an important role in sensing cellular stress (Fu et al., 2012). Physiological states that 
disrupt ER homeostasis create an imbalance between the protein-folding load and the ER’s 
capacity to fold proteins, resulting in unfolded or misfolded proteins that accumulate in the ER 
lumen (ER stress). To ensure the accuracy of protein folding and to prevent accumulation of 
such proteins, eukaryotic cells have developed the unfolded protein response (UPR). The UPR 
is a cellular mechanism of inhibiting protein synthesis, increasing protein folding and 
increasing ER-associated protein degradation in order to reduce the ER load of unfolded 
protein (Kaplowitz et al., 2007). This response is mediated by 3 ER-localized protein sensors: 
inositol-requiring enzyme 1α (IRE1α), double-stranded RNA-dependent like ER kinase 
(PERK), and activating transcription factor 6 (ATF6) (Fu et al., 2012).   Each protein sensor 
spans the ER membrane and consists of 3 domains; an ER-luminal domain that senses 
unfolded proteins, a transmembrane domain and a cytosolic domain that conveys signals to the 
transcriptional or translational apparatus. Under normal physiological conditions, these ER 
sensors are associated with the protein folding chaperone glucose-regulated protein 78 
(GRP78) (also known as binding immunoglobulin protein, BiP) at their luminal domains and 
maintained in an inactive state (Fu et al., 2012). Under conditions of ER stress, GRP78 binds 
to unfolded or misfolded proteins, resulting in the release and subsequent activation of the ER 
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stress sensors. Following the release of GRP78 from PERK, PERK phosphorylates eukaryotic 
translation initiation factor 2 α (eIF2α). Phosphorylation of eIF2α blocks global protein 
synthesis while selectively increasing translation of certain mRNAs, such as activating 
transcription factor 4 (ATF4). ATF4 promotes apoptosis under severe stress conditions (Lu et 
al., 2012). In response to ER stress, IRE1α, by autophosphorylation, initiates expression of the 
spliced form of X box binding protein 1 (XBP-1) which activates the transcription of genes 
encoding protein folding chaperones and factors that regulate maturation, secretion, and ER-
associated protein degradation. Meanwhile, the release of GRP78 from ATF6 allows ATF6 to 
translocate to the Golgi apparatus, become cleaved and, similar to XBP-I, activate the 
expression of UPR target genes (Fu et al., 2012). If ER stress is prolonged or the UPR is 
unable to maintain homeostasis, the ER stress response is initiated, which induces 
proinflammatory and proapoptotic pathways. These include activation of c-jun-N-terminal 
kinase (JNK) and increased C/EBP-homologous protein (CHOP) expression, which go on to 
activate apoptotic pathways (Kaplowitz et al., 2007). ER-stress induced apoptosis can involve 
mitochondria, which are recruited by ER signals such as calcium release. Increased expression 
of GRP78 and CHOP are characteristic markers of the UPR and the ER stress response, 
respectively, and have been shown to be activated under conditions of ER stress in 
hepatocytes both in vitro and in vivo (Kaplowitz et al., 2007). In the present study, GRP78 is 
used as a marker of the UPR in hepatocytes.  
Increasing evidence suggests that ER stress acts as an upstream signal in saturated fatty 
acid-induced apoptosis in many cell types, including hepatocytes. Chronic exposure of 
cultured hepatocytes to long-chain saturated fatty acids leads to upregulation of UPR and ER 
stress markers (CHOP, GRP78, phosphorylated PERK and phosphorylated eIF2α), followed 
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by cell death (Wei et al., 2006; Wei et al., 2009; Lee et al., 2010). Mechanisms of saturated 
fatty acid-induced ER stress involve release of ER luminal calcium stores and activation of 
caspases  (Wei et al., 2009; Wei et al., 2007). In vivo, both dietary and genetic models of 
hepatic steatosis are associated with upregulation of GRP78, CHOP, phosphorylated PERK 
and XBP-1 splicing (Ozcan et al., 2004; Wang et al., 2006; Rahman et al., 2007). Furthermore, 
saturated fatty acids can cause direct induction of ER stress by becoming incorporated into the 
saturated phospholipid and triglyceride species of the ER membrane, thereby compromising 
its structure and function (Borradaile et al., 2006b).  
1.3.3 Oxidative Stress 	  
In addition to ER stress, recent studies have suggested that oxidative stress, indicated 
by elevated levels of reactive oxygen species (ROS), is involved in the hepatocyte lipotoxic 
response (Li et al., 2008; Wu et al., 2008; Li et al. 2009). ROS are involved in cellular 
signaling and homeostasis. However, cell stress, mitochondrial dysfunction and decreased 
antioxidant defenses can lead to the overproduction of ROS (Leamy et al., 2013). This can 
cause damage to proteins, lipids and DNA, as well as compromise membrane integrity and 
organelle function, thereby inducing cell death (Brookheart et al., 2009). The elevated levels 
of ROS associated saturated fatty overload in hepatocytes (Li et al., 2008) can be attributed to 
various sources. Possible mechanisms include increased expression of cytochrome P450 2E1 
(CYP2E1) (the enzyme responsible for the oxidative metabolism of various substrates), 
upregulation of NADPH oxidase and increased mitochondrial β-oxidation  (Aubert et al., 
2011; Lambertucci et al., 2008; Inoguchi et al., 2000; Cacicedo et al., 2005; Nakamura et al., 
2009). However, the exact role of β-oxidation in promoting lipotoxic ROS accumulation is 
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unclear, suggesting that lipids play a complex role in generating ROS, which likely involves 
multiple mechanisms (Leamy et al., 2013).  
1.3.4 Mitochondrial Dysfunction 
 
Studies using primary mouse hepatocytes and HepG2 cells show that supplementation 
with long chain free fatty acids results in Bcl-2-associated X protein (Bax) translocation to the 
lysosome, lysosomal permeabilization and activation of cathepsin B, a lysosomal cysteine 
protease. This is followed by mitochondrial dysfunction, characterized by mitochondrial 
depolarization, cytochrome c release into the cytosol and increased generation of ROS (Li et 
al., 2008). Pharmacological inhibition of cathepsin B activation and mitochondrial cytochrome 
c release results in decreased free fatty acid induced lipid accumulation and hepatocyte 
apoptosis  (Wu et al., 2008; Cheng et al., 2009). Moreover, in liver tissue of patients with 
NASH, mitochondrial function is impaired, as reflected by impaired mitochondrial respiratory 
chain activity (Pérez-Carreras et al., 2003). In addition to these functional abnormalities, 
structural changes, such as longitudinal or spherical swelling and the development of 
intramitochondrial crystals, are observed in patients with steatohepatitis. It is thought that 
intramitochondrial crystals consist of phospholipids, and are perhaps formed in response to 
oxidative stress (Caldwell et al., 2009). Taken together, these findings suggest that 
mitochondrial dysfunction plays a role in the pathogenesis of lipotoxicity.  
ER stress is closely linked to oxidative stress (Zhang and Kaufman, 2008). Oxidative 
stress-induced apoptosis requires the release of calcium stores from the ER lumen, which can 
lead to ER stress by impairing normal protein-folding functions (Scorrano et al., 2003; Rao et 
al., 2004). Together they lead to apoptosis by mitochondrial pathways and caspase activation 
	  	  	  
	  
14	  
(Wei et al., 2006; Li et al., 2008). A general model for lipotoxic cell death incorporating the  
pathways described above is shown in Figure 1.2. 
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Figure 1.2 Pathways involved in the cellular response to saturated fatty acid overload. 
During exposure to excess saturated fatty acids, cellular capacities to store them as 
triglycerides (lipid droplets) and to catabolize them through β-oxidation (mitochondria) are 
overwhelmed. The resultant production of ROS, from several potential sources, can induce ER 
stress. Palmitate can also be rapidly incorporated into complex lipids in the ER membrane 
resulting in dramatic impairment of the structure and integrity of the ER. Both oxidative stress 
and altered ER composition and integrity result in the release of ER calcium stores, triggering 
apoptotic cell death via mitochondria. 
 
 
	  	  	  
	  
16	  
1.4 Eukaryotic elongation factor 1A-1 
Eukaryotic elongation factor 1A-1 (eEF1A-1) was originally discovered as the factor 
responsible for catalyzing the binding of aminoacyl-tRNA (aa-tRNA) to the A-site of the 
ribosome during the elongation phase of protein synthesis (McKeehan and Hardesty, 1969), 
but is now known to mediate other cellular processes including protein degradation, apoptosis 
and cytoskeletal organization (Figure 1.3) (Mateyak and Kinzy, 2010). eEF1A-1 is one of two 
isoforms, the other being eEF1A-2, that share 92% amino acid sequence similarity (Kahns et 
al., 1998).  Both variants have similar functions with regards to peptide elongation, however 
they are differentially expressed (Kahns et al., 1998). eEF1A-1 is expressed ubiquitously in 
mouse and human tissues (Kahns et al., 1998; Knudsen et al., 1993) while eEF1A-2 is 
expressed tissue-specifically in skeletal muscle, brain and heart (Lee et al., 1992; Khalyfa et 
al., 2001). The liver exclusively expresses only the eEF1A-1 isoform (Knudsen et al., 1993; 
Newbery et al., 2007).  
1.4.1 Canonical role of eEF1A-1 
 
eEF1A-1 is activated upon GTP binding through a conformational change that triggers 
recruitment of  aa-tRNA. This complex then binds to the A-site of the ribosome, resulting in a 
quaternary complex. GTP is hydrolyzed to GDP following correct codon-anticodon interaction 
which requires the activity of eEF1B, a guanine nucleotide exchange factor (GEF), to promote 
GDP release and reactivation of the protein through passive binding of GTP (Mateyak and 
Kinzy, 2010). The phosphorylation status eEF1A-1 has been shown to serve as a regulatory 
mechanism for controlling protein synthesis at the elongation phase. For example, 
phosphorylation of eEF1A-1 at Ser300 by TGF-β inhibits protein synthesis by disrupting  
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Figure 1.3  Canonical and non-canonical functions of eEF1A-1.  The canonical function of 
eEF1A-1 is to bind aa-tRNA in a GTP-dependent manner and deliver it to the ribosome. The 
non-canonical functions include turnover of misfolded proteins, binding and bundling the actin 
cytoskeleton as well as other cytoskeletal components, and apoptosis. (Adapted from Mateyak 
and Kinzy, 2010)  
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binding to aa-tRNA (Lin et al., 2010). eEF1A-1 consists of three domains (I, II and III): 
domain I is the GTP-binding domain, domain II associates with the aminoacyl of aa-tRNA and 
domain III is primarily involved with binding to actin (Mateyak and Kinzy 2010). eEF1A-1 is 
abundant within the cell, comprising 1-2% of total cellular protein in normal growing cells 
(Ejiri et al., 2002). However, cellular levels of eEF1A-1 are not rate limiting for protein 
synthesis (Condeelis, 1995). Its high cellular concentration and proximity to the ribosome 
suggests a role for eEF1A-1 in the control and accuracy of peptide elongation. This is 
supported by data that eEF1A-1 plays a role in the quality control of newly-synthesized 
proteins by binding nascent or unfolded proteins that are no longer associated with the 
ribosome, but not to correctly folded proteins (Hotokezaka et al., 2002). eEF1A-1 was 
identified as a factor required for the degradation of N alpha-acetylated proteins (Gonen et al., 
2004) and has been shown to bind damaged nascent proteins that are ubiquinated to facilitate 
their delivery to the proteasome (Chuang et al., 2005). Studies investigating the intracellular 
localization of eEF1A-1 indicate it is predominantly localized in the cytosolic compartment 
associated with endoplasmic reticulum, and specifically ribosomes (Hayashi et al., 1989; 
Minella et al., 1996; Didichenko et al., 1991).  
1.4.2 Association with the Cytoskeleton 
 
In addition to its function in peptide elongation, recent studies have presented evidence 
for a role of eEF1A-1 in cytoskeletal reorganization.  eEF1A-1 was originally identified as an 
actin-binding protein by Yang et al (1990). In this study, it was shown that eEF1A-1 can bind 
the actin cytoskeleton in a reversible manner (Yang et al., 1990). Others have indicated that 
eEF1A-1 localizes with F-actin by fluorescence microscopy (Dharmawardhane et al., 1991; 
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Collings et al., 1994). eEF1A-1 regulates the actin cytoskeleton through its G-actin binding 
and F-actin bundling activity, and has been demonstrated to alter the rate of actin 
polymerization (Gross and Kinzy, 2005; Murray et al., 1996; Doyle et al., 2011). Furthermore, 
studies using a genetic screen have identified the specific regions of eEF1A-1 responsible for 
actin binding, which are primarily located in domain III. Mutations in these regions lead to 
reduced actin binding and disorganization of the actin cytoskeleton (Gross and Kinzy, 2005, 
2007; Liu et al., 2002). It has also been suggested that eEF1A-1 functions in microtubule 
dynamics. In vitro experiments demonstrate that eEF1A-1 can bundle and stabilize 
microtubules (Durso and Cyr, 1994; Moore et al., 1999), while others have indicated it is 
involved with the severing of microtubules (Shiina et al., 1994).  
1.4.3 Role in Apoptosis 
 
eEF1A-1 has been reported to play an important role in mediating apoptosis. Early 
studies in mouse fibroblasts show that eEF1A-1 protein levels correlate with the rate of 
apoptosis during conditions of cell stress. In fact, eEF1A-1 overexpression accelerates the rate 
of apoptosis (Duttaroy et al., 1998). Both oxidative and ER stress induce its expression and it 
plays an important role in mediating apoptosis under these conditions (Chen at al., 2000; 
Borradaile et al., 2006a). Furthermore, recent evidence suggests a role for eEF1A-1 in anoikis 
(apoptosis due to loss of cell anchorage) (Itagaki et al., 2012). eEF1A-1 overexpression at the 
plasma membrane increases susceptibility of fibroblasts to anoikis during serum starvation 
conditions, while disrupting the increase in eEF1A-1 at the plasma membrane by small 
interfering RNA (siRNA) renders cells more resistant to anoikis (Itagaki et al., 2012). The pro-
apoptotic activity of eEF1A-1 appears to depend on its ability to regulate the cytoskeleton 
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(Shiina et al., 1994; Kato et al., 1997; Borradaile et al., 2006a), which undergoes dramatic 
changes during apoptosis (Ndozangue-Touriguine et al., 2008). 
1.5 Objectives and Hypothesis 
Through a genetic screen using a ROSAβgeo retroviral promoter trap in CHO cells to 
identify factors that, when disrupted, confer resistance to saturated fatty acid-induced 
apoptosis, eEF1A-1 was identified as a mediator of lipotoxic cell death (Borradaile et al., 
2006a). In isolated cardiomyocytes exposed to excess palmitate, eEF1A-1 protein expression 
increased in association with oxidative stress, and ER stress. Oxidative stress, ER stress, and 
induction of eEF1A-1 all preceded apoptotic cell death. Knocking down eEF1A-1 expression 
conferred resistance to palmitate-induced cell death through the prevention of changes in 
polymerized actin content that normally precede apoptosis (Borradaile et al., 2006a). In vivo, 
eEF1A-1 expression is induced in steatotic myocardium of mice with cardiac-specific 
lipotoxicity, in association with upregulation of markers of oxidative and ER stress 
(Borradaile et al., 2006a).  
Both the heart and the liver are key organs in the metabolism of fatty acids, and are 
significantly impacted by the progressive steatosis that occurs during obesity and metabolic 
disease (Szendroedi and Roden, 2009). The studies in this thesis extend the previous findings 
in cardiomyocytes, outlined above, to hepatocytes and steatotic liver.  
 
Hypothesis: eEF1A-1 protein responds to lipid overload induced stress in hepatocytes and in 
the livers of obese mice, and participates in the process of lipotoxicity. Furthermore, the 
mechanism of action of eEF1A-1 in promoting cell death involves its ability to regulate the 
actin cytoskeleton. 
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Objectives  
 
The specific objectives of this research project are to: 
 
1. Determine whether hepatic eEF1A-1 expression is induced in obese mice, in association 
with ER stress.  
 
2. Determine whether eEF1A-1 responds to fatty acid overload, or the direct induction of 
oxidative and ER stress in hepatocytes.  
 
3. Assess the localization of eEF1A-1 to the ER and to polymerized actin during lipid overload 
conditions.  
 
4. Determine whether targeted knockdown of eEF1A-1 expression confers resistance to 
saturated fatty acid-induced cell death, and whether its elongation function plays a role in the 
lipotoxic response.   
 
 
Relevance to Disease 
 As discussed previously, eEF1A-1 responds to lipid overload and has been identified as 
a key factor in mediating lipotoxic cell death (Borradaile et al., 2006a). NAFLD associated 
with obesity is becoming an increasingly prevalent condition and further studies are required 
to better understand its cause and progression. It is not yet known whether eEF1A-1 plays a 
role in the hepatocyte lipotoxic response. Understanding whether eEF1A-1 plays a significant 
role in mediating lipotoxicity in the liver will provide insight into the pathways involved in 
this complex disease.  This study could have implications for developing therapeutic targets to 
slow the progression of NAFLD. 
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2.0 MATERIALS AND METHODS 
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2.1 Mice 
Studies were performed in accordance with the Canadian Guide of the Care and Use of 
Laboratory Animals and were approved by the Western University Animal Care Committee. 
Five-week old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were fed ad 
libitum a chow diet (4% calories from fat, TD8604: Harlan Teklad, Madison, WI) or a high fat 
Western diet (42% of calories from fat plus cholesterol (0.05% wt/wt), TD96125; Harlan 
Teklad) for 16 weeks. Five week old male 129SvEv were fed ad libitum a chow diet or high 
fat Western diet for 15 weeks as described above. Six week old male C57BL/6J mice and 
leptin-deficient (ob/ob) mice were maintained on AIN-76A Semi-Purified Diet (Harlan 
Teklad) for 4 weeks. Food intake was measured daily and body weight was measured 
biweekly. Plasma triglycerides and total cholesterol were determined by enzymatic, 
colorimetric assays with reagents obtained from Roche Diagnostics. Blood glucose was 
determined using an Ascensia Elite glucometer (Bayer Healthcare, Toronto, Canada). Plasma 
insulin was measured using ultrasensitive mouse-specific enzyme-linked immunosorbent 
assays (ELISA) (Alpco Diagnostics, Windham, NH). Total liver lipids were extracted from 1.0 
g sections of liver that had been obtained at sacrifice and stored at -80 °C. Free cholesterol, 
cholesterol ester and triglycerides from chloroform extracts of liver tissue were determined by 
enzymatic, colorimetric assays using reagents obtained from Roche Diagnostics and Wako 
Diagnostics. All plasma and liver lipid measurements were performed through the Metabolic 
Phenotyping Laboratory in Robarts Research Institute. For analyses of hepatic protein 
expression, livers were harvested, snap frozen in liquid nitrogen, and tissue homogenates were 
prepared in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors. 
eEF1A-1 and GRP78 levels from 20 µg of tissue homogenates were determined by 
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immunoblotting as described below. Bands were quantified by densitometry and normalized to 
actin.    
2.2 Cell Culture 
 
HepG2 cells were obtained from the American Type Culture Collection (Rockville, 
MD) and grown on 100 mm culture dishes at 37°C and 5% CO2. Cells were maintained in 10 
ml of Eagles minimum essential medium (EMEM) (Lonza Biowhittaker) with 10% fetal 
bovine serum (FBS), 2 mM L-glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin and 0.5 
µg/ml fungizone (Life Technologies). Cells were split (1:6) on a 7 day cycle using trypsin-
EDTA. For experiments, cells were plated in 6-well (35 mm), 12-well (18 mm) or 24-well 
culture plates (Falcon).   
For fatty acid treatments, media was supplemented with 0.25 - 1.0 mM palmitate, 
oleate or a combination of palmitate and oleate (40:60 ratio). The concentrations of fatty acids 
used reflect high physiological to pathophysiological concentrations, as would be observed 
during obesity, metabolic syndrome, and type 2 diabetes.  The 40:60 ratio of palmitate to 
oleate is reflective of the saturated to unsaturated fatty acid composition of North American 
(Westernized) diets, and is maintained in circulating postprandial lipoprotein compositions 
(Gordon, 1960; Soriguer et al., 2009) For preparation of fatty acids, 20 mM solution of either 
palmitate or oleate in 0.01 M NaOH was heated to 70°C for 30 min. 1 N NaOH was added 
dropwise to facilitate solubilization. Fatty acids were complexed to 30% fatty acid free bovine 
serum albumin (BSA) (Sigma) at a fatty acid to BSA ratio of 2:1.  The complexed fatty acids 
were added to cell culture media to achieve a fatty acid concentration of 0.25 - 1 mM. BSA 
supplemented medium was used for control conditions. 
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2.3 Immunoblot Analyses 
 
Whole cell lysates were prepared using RIPA buffer (150 mM NaCl, 1.0% IGEPAL® 
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris-HCl, pH 8.0) (Sigma) 
supplemented with protease inhibitors and total cellular protein was quantified using the 
Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo Scientific, Rockford, IL). 
Lysates were centrifuged for 2 minutes at 14 000 rpm (20 800 gav) to eliminate insoluble 
material. Ten µg of whole cell lysate protein was diluted 1:1 with 2X Laemmli sample buffer 
(LSB) containing β- mercaptoethanol and heated to 100°C for 5 minutes. Samples were 
resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a 0.45 
µM nitrocellulose membrane using a semi-dry transfer apparatus. Membranes were incubated 
in 1% blocking buffer for 1 h. eEF1A-1 was detected following an overnight incubation at 4°C 
with a 1:7500 dilution of anti-eEF1A-1 mouse monoclonal antibody (Cell Signaling 
Technology), and a 1 h incubation with a 1:5000 dilution of a horseradish peroxidase (HRP)-
conjugated polyclonal anti-mouse antibody (Santa Cruz Biotechnology). GRP78 was detected 
following an overnight incubation with a 1:1000 dilution of anti-GRP78 rabbit polyclonal 
antibody (Sigma) and a 1 h incubation with a 1:5000 dilution of HRP-conjugated polyclonal 
anti-rabbit antibody (Santa Cruz Biotechnology). Actin was detected following an overnight 
incubation with a 1:2000 dilution of anti-actin rabbit polyclonal antibody (Sigma) and a 1 h 
incubation with a polyclonal anti-rabbit HRP secondary antibody, as described above. 
Membranes were washed 3 times for 5 min with Tris-buffered saline and 0.1% Tween-20 
(TBS-T) following incubation with primary and secondary antibodies. Blots were incubated 
with Enhanced Chemilumniscence Reagents (Thermo Scientific, Rockford, IL) for 1 min and 
exposed on film. Bands corresponding to actin ran between the 37 and 50 kD reference bands 
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of the Precision Plus Protein All Blue Standards (Biorad), bands corresponding to eEF1A-1 
ran beside the 50 kD reference band, and bands corresponding to GRP78 ran beside the 75 kD 
reference band. Bands were quantified by densitometry using Quantity One 1-D Analysis 
Software (Biorad) and normalized to actin.   
2.4 Cell Death  
Apoptosis and cell death were assessed by Alexa Fluor 488 annexin V staining and 
membrane permeability to propidium iodide, respectively, using the Dead Cell Apoptosis Kit 
(Molecular Probes). Following 48 h incubations with various treatments, cells were washed in 
cold phosphate-buffered saline (PBS) and harvested by trypsinization. 1X annexin-binding 
buffer was prepared by adding 1 mL 5X annexin binding buffer to 4 mL deionized water, and 
100 µg/mL working solution of propidium iodide (PI) was prepared by diluting 1 mg/mL PI 
stock solution in 45 µL 1X annexin-binding buffer. Cells were centrifuged and resuspended in 
1X annexin-binding buffer at a density of 1 x 106 cells/ml. After adding 2.5 µl Alexa Fluor 488 
annexin V and 2 µl PI to each 200 µl of cell suspension, cells were incubated at room 
temperature for 15 minutes in the dark. Samples were analyzed by flow cytometry with 
quantification of 104 cells/sample. Apoptotic cells were defined as annexin V positive and PI 
negative, indicating an intact plasma membrane. Dead cells were defined as annexin V 
positive and PI positive or PI positive alone, while live cells were negative for both annexin V 
and PI. Fluorescence emission was measured at 530 nm and >575 nm using 488 nm excitation.  
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2.5 Immunofluorescence Confocal Microscopy 
HepG2 cells were plated on cover glass slides in 6-well plates and allowed to adhere 
overnight. Once at 70-80% confluence, cells were incubated for 6 h with growth media 
containing BSA alone, 1.0 mM palmitate, oleate, or a combination of palmitate and oleate 
(40:60 ratio). Cells were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton 
X-100, then blocked for 15 min in 0.2% BSA and 10% horse serum in PBS. Following the 
blocking step, cells were incubated with anti eEF1A-1 monoclonal antibody (1:100 diluted in 
blocking buffer) for 1 h, washed 2 times for 5 min in PBS then incubated with a 1:100 dilution 
of FITC-conjugated secondary antibody 30 min. For visualization of ER, cells were incubated 
with anti-calnexin monoclonal antibody (1:1000) followed by a 1:2000 dilution of secondary 
antibody conjugated to Alexa Fluor 546 for 30 min. To visualize lipid droplets, cells were 
stained with Oil Red O (Sigma Aldrich). Staining solution was prepared fresh on day of use by 
dissolving 0.2 g of Oil Red O powder into 40 ml isopropanol. Working solution was prepared 
by mixing 30 ml stock solution with 20 ml PBS and filter sterilizing using a 0.22 µm syringe 
filter. To visualize polymerized actin (F-actin), cells were incubated with rhodamine 
phalloidin for 15 minutes followed by 5 minute washes (repeated 3 times) in PBS.  All 
coverslips were mounted onto glass slides with mounting media containing DAPI to visualize 
nuclei (ProLong Gold Antifade Reagent with DAPI, Molecular Probes). Cells were imaged by 
confocal laser scanning microscopy (Zeiss LSM 510 Meta Confocal Microscope) at the 
London Regional Cell and In Vitro Molecular Imaging Facility at Robarts Research Institute, 
and images were processed with Zeiss LSM 5 Image Browser. Colocalization was quantified 
through Image J using Pearson’s correlation coefficient (Rr), which is a standard statistical 
	  	  	  
	  
28	  
analysis designed to measure the strength of a linear relationship between two variables, in 
this case fluorescent intensities from two images (Barlow et al., 2010). 
2.6 Subcellular Fractionation 
HepG2 cells were plated and grown to confluence in 10 cm dishes and incubated with 
BSA or palmitate for 6 h as described previously. Cells were harvested in 250 mM sucrose 
and 10 mM Tris HCl containing protease inhibitors and homogenized using a Dounce 
homogenizer.  The homogenate was centrifuged at 800 x gav for 10 minutes to yield a nuclear 
pellet and a post-nuclear supernatant. The supernatant was centrifuged at 10 000 x gav for 10 
minutes to yield a mitochondrial pellet and a post-mitochondrial supernatant. The post-
mitochondrial supernatant was layered over a 1.3 M sucrose cushion and centrifuged at 202 
000 x gav for 2.5 hours to yield three distinct fractions: a post-microsomal supernatant 
representing cytosol, a fraction at the interphase of the sucrose cushion representing smooth 
microsomes and the Golgi apparatus, and a pellet fraction representing rough microsomes. 
RIPA buffer containing protease inhibitors was added to the smooth and rough microsomal 
fractions. eEF1A-1 and GRP78 levels from 25 µg of isolated subcellular fractions were 
determined by immunoblotting as described above. 
2.7 [3H] Leucine Incorporation Assay 
HepG2 cells were plated in 24-well plates, grown to 70-80% confluency and treated 
with increasing concentrations of didemnin B (up to 200 nM) or DMSO as a control, for 48 h. 
Didemnin B was obtained from the Open Chemical Repository of the Developmental 
Therapeutics Program at the National Cancer Institute (NIH).  Following treatment, 1 µL [3H] 
leucine was added to 250 µl growth medium per well for a specific activity of 500 kBq/ml. 
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Cells were incubated at 37°C for 60 min. Cells and culture media (for quantification of 
synthesis of both non-secreted and secreted proteins) were precipitated with cold 1 M 
trichloroacetic acid (TCA) for 60 min. A sample for total protein quantification was taken 
prior to precipitation. Samples were centrifuged at 12 000 rpm for 2 min at 4°C and washed 3 
times in 100% ethanol by resuspension and centrifugation. The pellet was solubilized in 1 N 
NaOH and samples were prepared for scintillation counting. Counts measured represented the 
amount of [3H] leucine incorporated into newly synthesized protein, and were expressed 
relative to total protein for each sample.  
2.8 MTT Assay 
HepG2 cells were plated at 50 000 cells per well in a 96-well plate and treated with 
increasing concentrations of didemnin B up to 200 nM or DMSO as a control for 48 h. Cell 
viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell-metabolism assay. MTT solution was prepared by dissolving 5 mg 
MTT/ml in sterile PBS at room temperature and filter sterilizing using a 0.2 µm syringe filter. 
Following treatment, 10 µl MTT was added to each well and incubated for 3 h at 37°C. 
Formazan crystals formed by the reduction of MTT were dissolved in extraction buffer 
consisting of 50 ml dimethylformamide (DMF), 50 ml ddH20 and 20 g SDS adjusted to pH 7.4 
and incubated overnight. Absorbance was quantified spectrophotometrically at a wavelength 
of 570 nm. The intensity of the coloured product formed is directly proportional to the number 
of live cells present in each sample.     
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2.9 Transfections 
Human eEF1A-1 cDNA sequence was used to design siRNA template oligonucleotides 
using the Ambion siRNA Target Finder tool. No commercially available pre-designed RNAi 
reagents are currently available that specifically target eEF1A-1. Hairpin siRNA template 
oligonucleotide sequences predicted to reduce eEF1A-1 expression were used to generate 
pSilencer 2.1-U6 expression vectors (Ambion) that were transfected into HepG2 cells. 
Transfected cells were selected by growth in 500 µg/ml hygromycin for 7 days. Two target 
sequences that were predicted to generate knockdown of protein expression were selected, 
however, following immunoblot analysis only one sequence, 5’-
AAGTCTGTAATGAAGTGTTAT-3’, was determined to efficiently reduce eEF1A-1 
expression. Cells expressing shRNA targeting this sequence were used for subsequent 
experiments. A control-shRNA expressing population was generated using scrambled shRNA 
constructs encoding no known target in which eEF1A-1 expression was not reduced.  
2.10 Statistical analysis 
Statistical analyses were performed using either Student’s t-Test or a one-way 
ANOVA followed by Tukey’s post hoc test. Differences in means were considered 
statistically significant at p < 0.05. Immunoblots were quantified by densitometry using 
Quantity One 1-D Analysis Software (Biorad) and normalized to actin. GraphPad Prism 
version 5.0 software was used for all statistical analyses and generation of graphs.  
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3.1 eEF1A-1 and GRP78 protein are increased in the liver of some mouse models of 
obesity with hepatic steatosis 
eEF1A-1 has been identified as a key mediator of lipotoxic cell death through a genetic 
screen in CHO cells (Borradaile et al., 2006a). In vivo, eEF1A-1 expression is induced in 
steatotic myocardium of mice with cardiac-specific lipotoxicity, in association with 
upregulation of markers of oxidative and ER stress (Borradaile et al., 2006a). In the present 
study, eEF1A-1 protein is increased in some mouse models of obesity, in association with ER 
stress. In obese, leptin deficient ob/ob mice maintained on AIN-76A diet for 4 weeks, hepatic 
eEF1A-1 and GRP78 protein increased 1.32 and 2.12-fold, respectively, compared to control 
C57BL/6J mice (Figure 3.1 A). In these mice, liver triglycerides and plasma insulin were 
elevated 8.9 and 30-fold, respectively (Table 3.1). In C57BL/6J mice maintained on a Western 
diet for 16 weeks, a 1.39-fold increase in hepatic GRP78 expression was observed while 
eEF1A-1 expression remained unchanged (Figure 3.1 B). These data suggests eEF1A-1 
expression may increase under conditions of hepatic stress caused by severe steatosis and 
insulin resistance. Interestingly, eEF1A-1 and GRP78 protein are decreased (17% and 42%, 
respectively) in the livers of 129SvEv mice maintained on a Western diet for 15 weeks 
compared to chow-fed control mice (Figure 3.1 C). Unlike the other mouse models of obesity, 
these mice were not hyperinsulinemic (Table 3.1). Increases in body weight, epididymal fat 
weight, plasma cholesterol, liver triglyceride and liver cholesterol ester were observed in both 
genetic and diet-induced models (C57BL/6J and 129SvEv) of obesity (Table 3.1). Together, 
data from C57BL/6J and 129SvEv mice fed a Western diet, as well as obese, leptin deficient 
ob/ob mice demonstrated positive correlations between eEF1A-1 protein expression with both   
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Figure 3.1 eEF1A-1 and GRP78 protein are increased in some mouse models of obesity 
with hepatic steatosis. eEF1A-1 and GRP78 protein were detected in whole tissue 
homogenates from livers of (A) 6 week old wild type (C57BL/6J) or leptin-deficient (ob/ob) 
mice maintained on AIN-76A diet for 4 weeks, (B) 5 week old C57BL/6J mice maintained 
on a chow or western diet for 16 weeks, (C) 5 week old 129SvEv mice maintained on a 
chow or western diet for 15 weeks. eEF1A-1 and GRP78 protein were detected by 
immunoblotting and quantified by densitometry for 6 chow and 6 western diet fed mice (for 
both 129SvEv and C57BL/6J strains) and 8 wild type (C57BL/6J) and 8 ob/ob mice. Data 
are expressed relative to actin. Representative blots are shown. All data are expressed as 
means ± SEM, * p < 0.05 
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Table 1 Parameters of metabolic disease in 3 mouse models of obesity and hepatic 
steatosis. Mice were maintained as described for Figure 1. Body weight, epididymal fat 
weight and liver weight were determined at sacrifice. Blood glucose was measured by 
glucometer. Plasma and liver lipids were measured enzymatically. Plasma insulin was 
measured by ELISA. Data are expressed as mean ± SEM, *p < 0.05 for 129SvEv or C57BL/
6J mice fed a chow diet compared to western diet and ob/ob mice compared to wild-type 
C57BL/6J mice.  
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liver triglyceride (Figure 3.2 A) and plasma insulin (Figure 3.2 B), and between GRP78 
expression and plasma insulin (Figure 3.2 D). 
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Figure 3.2 Hepatic eEF1A-1 expression correlates with liver triglyceride content and 
plasma insulin concentration. Liver triglycerides and plasma insulin are plotted against 
GRP78 and eEF1A-1 expression for 3 mouse models of obesity. 5 week old 129SvEv mice 
were maintained on a chow or western diet (WD) for 15 weeks, 5 week old C57BL/6J mice 
were maintained on a chow or western diet for 16 weeks and 6 week old wild type (C57BL/
6J) or leptin-deficient (ob/ob) mice were maintained on AIN-76A diet for 4 weeks. 
Triglycerides from chloroform extracts of liver tissue were quantified enzymatically, and 
plasma insulin was quantified by ELISA. eEF1A-1 and GRP78 protein were detected by 
immunoblotting and quantified by densitometry for 6 chow and 6 western diet fed mice (for 
both 129SvEv and C57B/6 strains) and 8 wild type (C57BL/6J) and 8 ob/ob mice. Protein 
are expressed relative to actin. Significant correlations (p < 0.05) are indicated with r2 value.  
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3.2 eEF1A-1 protein is rapidly induced in response to saturated fatty acid overload-
induced ER stress in HepG2 cells, an event that precedes cell death 
Having determined that eEF1A-1 is increased under conditions of severe hepatic 
steatosis and insulin resistance in mice, we set out to characterize and modulate expression 
levels of eEF1A-1 in an in vitro model to determine the role of this protein in the hepatocyte 
lipotoxic response. Previous studies showed that levels of eEF1A-1 increase in CHO cells and 
H9c2 rat cardiomyocytes in response to palmitate (Borradaile et al., 2006a).  In these cells, 
eEF1A-1 expression was rapidly induced (30 minutes and 1 h, respectively) and remained 
elevated for 5 h after treatment with palmitate (Borradaile et al., 2006a). For the present study, 
we selected HepG2 human hepatoma cells as an in vitro model of hepatocytes.  HepG2 cells 
are well suited for this application because, like human and rodent liver, and unlike other 
hepatocyte lines, they exclusively express the eEF1A-1 variant of eEF1A (Grassi et al., 2007; 
Newbery et al., 2007). In HepG2 cells incubated for 6 h with growth media containing either 
palmitate (1.0 mM) or a combination of palmitate and oleate (1.0 mM, 40:60 ratio), eEF1A-1 
protein increased 1.24-fold and 1.72-fold, respectively. In contrast, incubation with 1.0 mM 
oleate decreased eEF1A-1 expression by 16% (Figure 3.3 A). Changes in eEF1A-1 content 
were accompanied by similar changes in GRP78 content in palmitate treated cells, indicating 
the onset of ER stress under these lipid overload conditions (Figure 3.3 B).    
In addition to fatty acid induced cell stress, eEF1A-1 has been shown to be directly 
induced in response to oxidative and ER stress (Chen et al., 2000; Borradaile et al., 2006a). For 
the present study, H2O2 was used to induce oxidative stress and tunicamycin was used to induce 
ER stress. Tunicamycin inhibits protein glycosylation and subsequent protein folding, and is 
widely used as an inducer of ER stress and the UPR (Lee, 2001). An increasing trend in  
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Figure 3.3 eEF1A-1 expression is increased in HepG2 cells during fatty acid overload 
induced ER stress. HepG2 cells were incubated for 6 h with growth media containing BSA 
alone, palmitate (PA), oleate (OA) or a combination of palmitate and oleate (40:60 ratio) at 
concentrations of 0.25, 0.5 and 1.0 mM. All fatty acids were conjugated to BSA at a molar 
ratio of 2:1.  (A) eEF1A-1 and (B) GRP78 protein were detected in whole cell lysates by 
immunoblotting. All data were quantified by densitometry and normalized to actin. 
Representative blots are shown beside each graph. Fatty acid treatments are compared to the 
lowest respective concentration (0.25 mM). Data are expressed as mean ± SEM for 3-6 
independent experiments, *p < 0.05.  
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eEF1A-1 expression was noted following incubation with 1.0 µg/ml tunicamycin for 6 h. In 
addition, eEF1A-1 protein increased 1.97-fold in cells treated with 2.5 mM H202, indicating that 
eEF1A-1 expression in hepatocytes also responds to direct induction of oxidative stress (Figure  
3.4 A). GRP78 expression increased 2.41-fold following treatment with tunicamycin (Figure 
3.4 B). 
Saturated fatty acids are known to trigger cellular stress responses leading to apoptotic 
cell death in hepatocyte cell lines and primary hepatocytes, as well as in other cell types (Wei 
et al., 2006; Li et al., 2009). Consistent with these earlier studies, treatment of HepG2 cells 
with 1.0 mM palmitate for 48 h resulted in a 2.24 fold increase in the proportion of cell death 
compared to BSA treated cells (Figure 3.5). No difference in cell death was observed in oleate, 
or a combination of palmitate and oleate treated cells. 
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Figure 3.4 eEF1A-1 expression is increased in HepG2 cells in response to direct 
induction of oxidative or ER stress. HepG2 cells were incubated for 6 h with 2.5 mM H202 
or 1.0 µg/ml tunicamycin. Control cells were incubated for 6 h with water or DMSO, 
respectively. (A) eEF1A-1 expression and (B) GRP78 expression were detected at the 
protein level in whole cell lysates by immunoblotting. All data were quantified by 
densitometry and normalized to actin. Representative blots are shown below each graph. 
Tunicamycin and H202 treated cells are compared to control. Data are expressed as mean ± 
SEM for 3-6 independent experiments, *p < 0.05. 
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Figure 3.5  Palmitate induces lipotoxicity in HepG2 cells. 
Confluent HepG2 cells were incubated for 48 h with growth media containing BSA alone, 
1.0 mM PA, OA or a combination of PA and OA (40:60 ratio). All fatty acids were 
conjugated to BSA at a molar ratio of 2:1. Cells were harvested, stained with propidium 
iodide, and the proportion of dead cells was determined by flow cytometry. Fatty acid 
treatments are compared to BSA control. All data are expressed as mean ± SEM for 4-8 
independent experiments, *p < 0.05.  
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3.3 Palmitate induces eEF1A-1 colocalization with the actin cytoskeleton 
In addition to its canonical role in peptide elongation, eEF1A-1 is known to participate 
in remodeling of the actin cytoskeleton, which undergoes dramatic changes during apoptosis 
and cell death (Murray et al., 1996; Ndozangue-Touriguine et al., 2008). eEF1A-1 has also 
been reported to associate with lipid droplets and the ER in various cell types (Zhang et al., 
2011; Bouchoux et al., 2011; Chen et al., 2010; Minella et al., 1996). To assess the 
localization of eEF1A-1 with the actin cytoskeleton, as well as its association with lipid 
droplets and the ER in response to lipid overload, HepG2 cells were treated for 6 h with fatty 
acids, fixed, stained, and imaged by confocal fluorescent microscopy, as described in 
Materials and Methods.  
eEF1A-1 has been identified to associate with lipid droplets in proteomic analyses of 
neutral lipid droplets from mouse skeletal muscle and intestinal enterocytes (Zhang et al., 
2011; Bouchoux et al., 2011). However, our experiments indicated no colocalization of 
eEF1A-1 with cytosolic neutral lipid droplets in HepG2 cells in either of the fatty acid 
treatment conditions (Figure 3.6 C-F). As seen in Figure 3.6 G-H, enlargement of the outlined 
area indicates that eEF1A-1 surrounds lipid droplets but does not colocalize with or decorate 
these neutral lipid stores.  
eEF1A-1 has been found predominantly localized to the ER in fibroblast cells, 
particularly in association with ribosomes (Hayashi et al., 1989). Consistent with these studies, 
our confocal fluorescent microscopy images indicate that eEF1A-1 colocalizes with the ER in 
hepatocytes under basal conditions (Figure 3.7 C-F). Colocalization was quantified through 
ImageJ using Pearson’s correlation coefficient (Rr), in order to measure the strength of the  
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Figure 3.6 eEF1A-1 does not colocalize with lipid droplets in HepG2 cells.  HepG2 cells 
were incubated for 6 h with growth media containing BSA alone, 1.0 mM PA, OA or a 
combination of PA and OA (40:60 ratio). All fatty acids were conjugated to BSA at a molar 
ratio of 2:1. eEF1A-1 and lipid droplets were assessed by confocal fluorescent microscopy. 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and 
incubated with anti-eEF1A monoclonal antibody followed by secondary conjugated to FITC 
(green) to visualize EF1A-1 (A). Cells were stained with Oil Red O (ORO) to visualize 
neutral lipids (red) (B) and counterstained with DAPI to visualize nuclei (blue). Localization 
of eEF1A-1 with lipid droplets was assessed in cells treated with BSA (C), PA (D), OA (E) 
and a combination of PA and OA (F). Enlargement of the outlined area in (F) indicate that 
no colocalization was observed between eEF1A-1 and cytosolic neutral lipid droplets. 
Representative images from 3 independent experiments are shown. 
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Figure 3.7 eEF1A-1 colocalization with the ER is decreased during exposure to excess 
palmitate. HepG2 cells were incubated for 6 h with growth media containing BSA alone, 
palmitate (PA), oleate (OA) or a combination of palmitate and oleate (40:60 ratio) at 
concentrations of 0.25, 0.5 and 1.0 mM. All fatty acids were conjugated to BSA at a molar 
ratio of 2:1. eEF1A-1 and ER were assessed by confocal fluorescent microscopy. Cells were 
fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and incubated with 
anti-eEF1A monoclonal antibody followed by secondary conjugated to FITC (green) to 
visualize EF1A-1 (A). Cells were incubated with anti-calnexin monoclonal antibody 
followed by secondary conjugated to Alexa Fluor 546 (red) to visualize ER (B) and 
counterstained with DAPI to visualize nuclei (blue). Colocalization of eEF1A-1 with ER 
was assessed in cells treated with BSA (C), PA (D), OA (E) and a combination of PA and 
OA (40:60 ratio) (F). Colocalized signal is seen in yellow and was quantified using 
Pearson’s correlation coefficient (Rr) to assess overlap between signal for eEFIA-1 and 
calnexin (G). (H) eEF1A-1 protein levels were detected in cytosolic, smooth microsomal, 
and rough microsomal fractions isolated by sequential centrifugations in the absence or 
presence of palmitate (8 h treatment). GRP78 and actin were detected to determine the 
relative enrichment and contamination of each fraction. Representative blots are shown. All 
data are expressed as mean ± SEM for 3 independent experiments, *p < 0.05. 
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relationship between fluorescent intensities from two images (Barlow et al., 2010). This value 
ranges from -1.0 to 1.0, where 0 indicates random distribution, -1.0 indicates complete inverse 
correlation and 1.0 indicates complete positive correlation between fluorescent signals 
(Zinchuk and Grossenbacher-Zinchuk, 2009). In our experiments, the Rr for eEF1A-1 
colocalization with F-actin or ER ranged from -0.0023 to 0.60 in all treatments tested. In 
HepG2 cells incubated for 6 h in the presence of palmitate, a 30% decrease in colocalization 
of eEF1A-1 with the ER was observed compared to BSA treated cells (Figure 3.7 G). 
Subcellular fractionation of HepG2 cells confirmed that eEF1A-1 is enriched in ER fractions 
(Figure 3.7 H). 
The decrease in colocalization of eEF1A-1 with the ER in response to excess palmitate 
was accompanied by a corresponding increase (2.79-fold) in colocalization of eEF1A-1 with 
the actin cytoskeleton (Figure 3.8). Images constructed from a z-series of optical sections 
indicated that under basal conditions, F-actin was primarily localized to the basolateral surface 
of the cell monolayer while eEF1A-1 was localized apically (Figure 3.8 G). Treatment with 
palmitate resulted in increased colocalized signal at the basolateral surface (Figure 3.8 H).  
3.4 Inhibition of eEFA-1 elongation function decreases palmitate-induced cell death 
To determine whether the peptide elongation function of eEF1A-1 plays a role in the 
lipotoxic response, HepG2 cells were incubated with didemnin B, a member of a class of 
cyclic depsipeptides produced by ascidians (marine tunicates) that are known to have eEF1A-
1-dependent inhibitory effects on protein synthesis (Marco et al., 2003). Didemnin B 
specifically binds GTP-bound eEF1A-1 at the ribosome and inhibits its release from the 
ribosomal A-site, thus attenuating protein synthesis (Marco et al., 2003). HepG2 cells were 
treated for 48 h with increasing concentrations of didemnin B, followed by assessment of total  
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Figure 3.8 eEF1A-1 colocalization with the actin cytoskeleton is increased during 
exposure to excess palmitate. HepG2 cells were incubated for 6 h with growth media 
containing 1.0 mM palmitate PA conjugated to BSA (molar ratio 2:1), OA conjugated to 
BSA (molar ratio 2:1), a combination of palmitate and oleate (40:60 ratio), or BSA alone. 
eEF1A-1 and polymerized actin, and were assessed by confocal fluorescent microscopy. 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and 
incubated with anti-eEF1A monoclonal antibody for 1 h and secondary conjugated to FITC 
(green) for 30 min to visualize EF1A-1 (A). Cells were stained with rhodamine phalloidin to 
visualize F-actin (red) (B) and counterstained with DAPI to visualize nuclei (blue). 
Colocalization of eEF1A-1 with ER was assessed in cells treated with BSA (C), PA (D), OA 
(E) and a combination of PA and OA (40:60 ratio) (F). (G) and (H) show images 
constructed from a z-series of optical sections of cells treated with BSA and PA, 
respectively. Colocalized signal is seen in yellow and was quantified using Pearson’s 
correlation coefficient (Rr) to assess overlap between signal for eEFIA-1 and phalloidin (I). 
All data are expressed as mean ± SEM 4 independent experiments, *p < 0.05. 
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protein synthesis by [3H] leucine incorporation over 1 h (Figure 3.9 A).  Concentrations used 
were selected based on previous studies of didemnin B in human cancer cell lines (Beidler et 
al., 1999). The IC50 for inhibition of protein synthesis was determined to be 80 nM (Figure 3.9 
A). Cell viability, measured using the MTT cell-metabolism assay, was not affected at this 
IC50 concentration (Figure 3.9 B). In subsequent experiments, cells were treated with 1.0 mM 
palmitate in the presence or absence of 80 nM didemnin B for 48 h followed by assessment of 
cell death by flow cytometry. Treatment with palmitate in the presence of didemnin B 
decreased palmitate-induced cell death (Figure 3.9 C), suggesting that the elongation function 
of eEF1A-1 may play a role in the lipotoxic response.  
 
3.5 Modest long-term inhibition of eEF1A-1 expression alters HepG2 morphology 
 
Previous studies showed that knockdown of eEF1A-1 expression in CHO cells and 
H9c2 cardiomyocytes conferred resistance to palmitate-induced cell death (Borradaile et al., 
2006a). To extend these findings to hepatocytes, a cell type that, similar to cardiomyocytes, is 
affected by lipotoxicity in metabolic disease, we generated two populations of HepG2 cells 
with stable expression of shRNA predicted to target eEF1A-1 message. Control cells 
expressed an shRNA construct encoding no known target. Upon assessment of the extent of 
eEF1A-1 knockdown by immunoblotting, only one population (EF shRNA) was identified as 
having significantly reduced eEF1A-1 expression (18%) (Figure 3.10 A).  This population was 
used for subsequent experiments. Although the reduction of eEF1A-1 expression in EF 
shRNA expressing cells is modest, this protein is abundant in cells and represents about 2% of 
total cellular protein (Ejiri et al., 2002). Thus small decreases in relative levels of eEF1A-1 
reflect large decreases in total protein production. Unlike in H9c2 cardiomyocytes,  
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Figure 3.9 Inhibition of eEF1A-1 elongation function decreases palmitate-induced cell 
death.  HepG2 cells were treated for 48 h with increasing concentrations of didemnin B 
(inhibitor of eEF1A-1 elongation function), or DMSO as a control, followed by assessment 
of total protein synthesis by [3H] leucine incorporation. The IC50 for inhibition of protein 
synthesis was 80 nM. (B) Cells were incubated as described above, followed by incubation 
for 3 h with 5 mg/ml MTT. MTT reduction, indicative of cell viability, was quantified 
spectrophotometrically at a wavelength of 570 nm. (C) HepG2 cells were incubated for 48 h 
with growth media containing 1.0 mM PA conjugated to BSA (molar ratio 2:1) in the 
presence or absence of 80 nM didemnin B (IC50). Cells were harvested, stained, and the 
proportions of live cells (Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI
+) were determined by flow cytometry. For A and B, data are expressed as percentage of 
control ± SEM for 3 independent experiments. For C, data are expressed as mean ± SEM for 
4 independent experiments, *p < 0.05 for PA compared to BSA control.  
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Figure 3.10 Modest long-term inhibition of eEF1A-1 expression alters HepG2 
morphology. HepG2 cell lines were generated expressing either control shRNA against no 
known target, or shRNA targeted against eEF1A-1 (EF shRNA) (A). eEF1A-1 protein levels 
from whole cell lysates were detected by immunoblotting. All data were quantified by 
densitometry and normalized to actin. A representative blot from 5 independent experiments 
is shown (A). (B) Control shRNA and EF shRNA expressing cells were incubated for 48 h 
with growth media containing 1.0 mM PA conjugated to BSA (molar ratio 2:1) or BSA 
alone. Cells were harvested, stained with ann V and PI, and the proportions of live cells 
(Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI+) were determined by 
flow cytometry. PA treated cells are compared to BSA for both control and EF shRNA 
expressing cells. Data are expressed as mean ± SEM for 3 independent experiments, *p < 
0.05. (C) Cell morphology of control shRNA or EF shRNA expressing cells and DMSO or 
didemnin B treated wild-type HepG2 cells.  
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knockdown of eEF1A-1 expression was not accompanied by resistance to palmitate-induced 
cell death (Figure 3.10 B). However, EF shRNA expressing cells exhibited altered cell 
morphology compared to control shRNA expressing cells (Figure 3.10 C). EF shRNA 
expressing cells exhibited elongated projections extending from the cell body and enlarged 
spherical structures, resembling vacuoles, within the cell body. This altered morphology was 
not evident in wild-type HepG2 cells treated with didemnin B, thus these morphological 
changes are not likely due to inhibition of the canonical elongation function of eEF1A-1 alone.  
Taken together this data suggests that eEF1A-1 expression is induced in the livers of 
obese mice as well as in HepG2 human hepatoma cells in response to excess palmitate, and 
may participate in the process of lipotoxicity by mediating changes in protein synthesis related 
to actin cytoskeleton remodeling that occur during cell stress. 
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4.0 DISCUSSION 
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4.1 Summary of Results  
 As much as 30% of the general population is currently affected with NAFLD, while the 
prevalence in the morbidly obese is estimated at 75-92%, making this condition one of the 
most common liver disorders worldwide (Trauner et al., 2010; Erickson, 2009). However, the 
cause and progression of NAFLD is complex and not fully understood. Based on previous 
findings identifying eEF1A-1 as a mediator of lipotoxic cell death in CHO cells and 
cardiomyocytes, a similar role for this protein in hepatocytes was proposed. We hypothesized 
that eEF1A-1 protein responds to lipid overload in hepatocytes and in the steatotic livers of 
obese mice, and participates in the process of lipotoxicity. Furthermore, we proposed that the 
mechanism of action of eEF1A-1 in lipotoxicity may involve its ability to regulate the actin 
cytoskeleton. Our studies have revealed several key findings. 1) eEF1A-1 protein is induced, 
in association with ER stress, in a mouse model of obesity with severe hepatic steatosis, and in 
cultured hepatocytes exposed to excess saturated fatty acids. 2) A consequence of palmitate 
overload in hepatocytes is increased colocalization of eEF1A-1 with the actin cytoskeleton and 
decreased colocalization with the ER, followed by cell death, suggesting eEF1A-1 may 
regulate changes in the actin cytoskeleton required for the progression of cell death. 3) 
Inhibition of the elongation function of eEF1A-1 diminishes palmitate induced cell death, 
while modest long-term inhibition of eEF1A-1 expression alters hepatocyte morphology with 
no effect on palmitate-induced cell death, suggesting that the canonical function of eEF1A-1 
may play a role in lipotoxicity.  
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4.2 eEF1A-1 in mouse models of obesity and hepatic steatosis 
 Our data from diet induced and genetic models of obesity indicate that eEF1A-1 protein 
content is increased under conditions of hepatic stress associated with severe steatosis and 
insulin resistance. In addition to findings that eEF1A-1 protein is increased in steatotic mouse 
myocardium (Borradaile et al., 2006a), changes in its expression have been reported in several 
other obese and diabetic models. In an analysis of the dysregulated genes associated with 
chronic hepatic steatosis, eEF1A-1 expression was increased in hepatocytes isolated from 
obese insulin-resistant Zucker rats compared to lean littermates (Buqué et al., 2009). 
Furthermore, others have shown that EF1A-1 expression is increased in the skeletal muscle of 
both type 1 and type 2 diabetic patients, in skeletal muscle of streptozotocin-induced diabetic 
rats (Reynet and Kahn, 2001), and in the renal cortex of diabetic rats (Al-Maghrebi et al., 
2005). These previous findings, along with our own observations that eEF1A-1 protein 
expression is positively correlated with both liver triglyceride and plasma insulin, suggest 
eEF1A-1 may play a role in the cellular pathways responsible for the pathogenesis of 
metabolic syndrome.  
 
4.3 eEF1A-1 as a response protein during saturated fatty acid induced ER stress and cell 
death 
 In the present study, we show that eEF1A-1 responds to palmitate overload in 
hepatocytes, consistent with previous findings in CHO cells and cardiomyocytes (Borradaile et 
al., 2006a). Palmitate is the most common saturated fatty acid in our diet and cells were 
treated with concentrations of fatty acids (up to 1.0 mM) that mimic those encountered in 
pathophysiological conditions. We further found that eEF1A-1 protein was induced in cells 
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treated with a combination of palmitate and oleate (40:60 molar ratio), which has not been 
reported previously in any cell type. Of note, treatment with palmitate plus oleate was not 
severe enough to induce ER stress or cell death, as was seen in palmitate treated HepG2 cells. 
However, this combination is most similar to the fatty acid composition of North American 
(Westernized) diets suggesting these results may have implications in vivo.  
  
4.4 Subcellular localization of eEF1A-1 during fatty acid overload 
 eEF1A-1 is known to bind to and regulate polymerization of the actin cytoskeleton 
(Shiina et al., 1994; Murray et al., 1996). Because the cytoskeleton undergoes dramatic 
changes during apoptosis and cell death, we wanted to determine the subcellular localization 
of eEF1A-1 under basal and lipid overload conditions in hepatocytes.  Our initial findings 
indicated relatively low colocalization of eEF1A-1 with the actin cytoskeleton under basal 
conditions. Our images constructed from a z-series of optical sections indicate that, under 
basal conditions, actin is primarily localized to the basolateral surface of the cell monolayer, 
while eEF1A-1 is localized apically. These observations likely explain our difficulty in 
acquiring confocal microscopy images in which the two proteins are present in the same 
optical plane. Our finding that palmitate treatment increased colocalization of eEF1A-1 with 
the actin cytoskeleton, combined with previous evidence that palmitate treatment can increase 
polymerized actin content (Borradaile et al., 2006a) suggest that the response of eEF1A-1 to 
saturated fatty acids in hepatocytes may involve regulation of cytoskeletal dynamics by 
promoting actin polymerization.  Similar effects on actin distribution are seen in cells treated 
with H202, preceding cell death (Dalle-Donne et al., 2001; Zhu et al., 2005), conditions which 
we showed also induce eEF1A-1 protein. Our finding that EF1A-1 localizes to the actin 
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cytoskeleton and toward the basolateral surface of the cell during palmitate-induced stress may 
also indicate increased localization at cell membrane surfaces that are in contact with the 
surface of the cell culture plate.  This is consistent with recent evidence indicating that eEF1A-
1 plays a role in anoikis through increased localization to the cell membrane (Itagaki et al., 
2012) 
 Others have reported changes in the localization of eEF1A-1 to actin in response to 
external stimuli. Dharmawardhane et al. (1991) observed an increased incorporation of 
eEF1A-1 into the actin cytoskeleton upon stimulation with the chemoattractant cAMP in the 
actin-filament containing regions of the cell cortex and in the filopodia (Dharmawardhane et 
al., 1991). However, this response was not involved in promoting cell death, as is likely the 
case in our HepG2 cell experiments, but instead was involved with the extension of cell 
surface projections.  
 Our finding that eEF1A-1 is mainly localized in the cytoplasmic compartment of 
hepatocytes and colocalizes to the ER under basal conditions is consistent with findings in 
other cell types (Minella et al., 1996; Chen et al., 2010). We further show here for the first 
time that a decrease in colocalization of eEF1A-1 with the ER occurs following treatment with 
palmitate. Taken together, these data, along with our results that significant palmitate-induced 
cell death does not occur until 48 h, indicate that eEF1A-1 may mediate palmitate-induced cell 
death by translocation toward the actin cytoskeleton to regulate changes in actin 
polymerization required for the progression of cell death.  
 Although recent evidence from proteomic analyses of cytosolic lipid droplets suggests 
eEF1A-1 associates with lipid droplets in various metabolic tissue cell types (Bartz et al., 
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2007; Zhang et al., 2011; Bouchoux et al., 2011; Ding et al., 2012), our findings do not 
support these conclusions. Our confocal microscopy work indicates that eEF1A-1 does not 
associate with or decorate cytosolic lipid droplets, as is seen with other lipid droplet-associated 
proteins such as perilipin (Buers et al., 2011). This suggests that the association of eEF1A-1 
with lipid droplets reported in previous studies may be found in specific cellular components, 
such as the ER, that were co-purified with the lipid droplet fraction. Lipid droplet formation 
originates at the ER, where it is believed that neutral lipids accumulate to form a lens between 
the two leaflets of the phospholipid bilayer (Brasaemle and Wolins, 2012). The fact that 
eEF1A-1 is highly localized to the ER makes it likely that biochemical isolation of lipid 
droplets for proteomic analyses results in a preparation that is contaminated with some ER 
localized proteins, including eEF1A-1.  
4.5 Inhibition of eEF1A-1 elongation function and response to lipotoxicity 
 Although the peptide elongation function of eEF1A-1 is well characterized, it has not 
been previously implicated in lipotoxicity.  Didemnin B is a naturally occurring cyclic peptide 
that inhibits protein synthesis by binding GTP-bound eEF1A-1 at the ribosome and preventing 
ribosomal translocation (Ahuja et al., 2000; Marco et al., 2004). Thus, it specifically inhibits 
the elongation function of eEF1A-1.  Since its discovery in 1981, didemnin B has been to 
show to have various antitumor, antiviral and immunosuppressive functions and was the first 
compound isolated from a marine source to go into clinical trials for human diseases (Lee et 
al, 2012).  
Work from several laboratories has suggested that accumulation of unfolded proteins 
in the ER and activation of the UPR itself is sufficient to cause hepatic steatosis (Imrie and 
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Sadler, 2012). This suggests a possible disease scenario in which increased fatty acid flux 
from adipose tissue to the liver initially induces ER stress, which in turn induces hepatic de 
novo lipogenesis, which subsequently worsens hepatic ER stress, leading to the progression of 
NAFLD.  Our results show that treatment with palmitate in the presence of didemnin B 
decreases palmitate-induced cell death, suggesting that the elongation function of eEF1A-1 
may play a role in the lipotoxic response. Thus, it is possible that inhibition of protein 
synthesis during palmitate overload may decrease the burden on the ER, which may prevent 
activation of the UPR, ER stress response and subsequent activation of downstream apoptotic 
pathways. This concept is supported by recent evidence that suggests alleviating ER stress and 
the accumulation of misfolded proteins may serve as a possible therapeutic strategy for the 
treatment NAFLD (Ibrahim et al., 2011). Small chemical chaperones such as glycerol or 4-
phenyl butyric acid (PBA) improve ER stress by increasing ER protein folding capacity and 
facilitate the appropriate trafficking of misfolded proteins (Clark and Diehl, 2003). Treatment 
of obese and diabetic mice with these compounds reduces ER stress, decreases hepatic 
steatosis and improves liver function enzyme levels (Ozcan et al., 2006). 
 
4.6 Knockdown of eEF1A-1 in hepatocytes and response to lipotoxicity 
 To determine whether knocking down eEF1A-1 expression could protect hepatocytes 
from palmitate-induced cell death, we generated a stable population of HepG2 cells in which 
eEF1A-1 expression was modestly reduced. We did not find that hepatocytes with reduced 
eEF1A-1 expression were protected from lipotoxic cell death. This may be explained by the 
limited extent of knockdown that was achieved (18% reduction). However, it is also possible 
	  	  	  
	  
69	  
that other, protective or adaptive functions of eEF1A-1 may be disrupted by reducing its 
expression – functions which may not be disrupted by didemnin B.  
 eEF1A-1 is highly expressed in the liver and in other tissues with high rates of protein 
synthesis and cell proliferation (lung, kidney, pancreas, placenta) (Knudsen et al., 1993). 
Although eEF1A-1 is not rate-limiting for protein synthesis, it has roles in many other cellular 
processes (Mateyak and Kinzy, 2010), therefore it is possible that hepatocytes with a greater 
reduction of eEF1A-1 were not be viable for extended periods of time.  Although no changes 
in the cell death response to palmitate were observed in our EF shRNA expressing HepG2 
population were observed, these cells exhibited an altered phenotype compared to control 
shRNA expressing cells. Interestingly, Gross and Kinzy (2005) noted a difference in 
morphology of cells in which the interaction between eEF1A-1 and actin was disrupted. Yeast 
with mutations in the eEF1A-1 domain responsible for actin binding were shown to be larger 
in size and exhibited pronounced elongated buds (Gross and Kinzy, 2005). Thus, it is possible 
that even a small reduction in total protein expression may be sufficient to disrupt eEF1A-1-
actin interactions and result in altered cytoskeletal organization.  
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Figure 4.1 Working model for the role of eEF1A-1 in hepatocyte response to saturated 
fatty excess. During exposure to excess saturated fatty acids, cellular capacities to store them 
as triglycerides (lipid droplets), to catabolize them through β-oxidation (mitochondria), or 
secrete them in the form of VLDL particles are overwhelmed. Under basal conditions, the 
majority of eEF1A-1 is localized to the ER and little is associated with the actin cytoskeleton. 
Palmitate overload leads to mobilization of eEF1A-1 away from the ER and toward the actin 
cytoskeleton to mediate changes in its structure, likely by promoting actin polymerization and 
potentially actin synthesis, for the progression of cell death. 
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4.7 Future Directions 
 Our working model for the role that eEF1A-1 plays in the stress response to saturated 
fatty acid excess in hepatocytes is summarized in Figure 4.1.  Based on this model, and our 
evidence of increased eEF1A-1 protein in the livers of obese, leptin-deficient mice with severe 
hepatic steatosis (ob/ob) mice, several future experiments are warranted.  
  To further support our evidence of the interaction between eEF1A-1 and the actin 
cytoskeleton during palmitate overload, I would like to determine if eE1A-1 functions by 
regulating cytoskeleton dynamics, as is seen in other cell types. To do so, I would disrupt the 
interaction of eEF1A-1 with the actin cytoskeleton by transfecting cells with a construct 
encoding domain III of eEF1A-1 (the dominant actin-binding domain). This construct is 
expected to have a dominant-negative action on the eEF1A-1-actin interaction. To induce lipid 
overload and cell death, cells will be treated with palmitate and cell death will be assessed by 
flow cytometry.  
 Based on our results that treatment with didemnin B reduces palmitate-induced cell 
death in HepG2 cells, future studies should be directed towards testing the effectiveness of 
didemnin B in improving hepatocyte damage in mouse models of NAFLD. The results 
presented in this thesis indicate that eEF1A-1 expression is increased in the livers of leptin 
deficient ob/ob mice and these animals exhibited the most severe form of hepatic steatosis and 
ER stress. Furthermore, ob/ob mice are a well-characterized model of NAFLD (Anstee and 
Goldin, 2006). Thus, I would select this model for subsequent didemnin B experiments.  
Previous work has demonstrated that didemnin B is highly concentrated in the livers of mice 
following intraperitoneal administration (Beasley et al., 2005). To determine if ER stress and 
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hepatocyte damage is attenuated in the livers of these mice treated with didemnin B, liver 
samples will be analyzed for GR78 expression, PERK phosphorylation and JNK activity. 
These markers of ER stress are consistently exhibited in ob/ob mice (Ozcan et al., 2004). 
Serum measurements of ALT and AST activity will be used as additional indicators of liver 
damage.  
The liver is composed of hepatocytes and non-parenchymal cells, which include 
kupffer cells, sinusoidal endothelial cells and hepatic stellate cells (Bian and Ma, 2012). 
Hepatic stellate cells play a key role in the hepatic fibrogenesis associated with NASH.  Under 
normal conditions, hepatic stellate cells are maintained in a quiescent state but can undergo a 
phenotypic transition to become activated in response to liver injury. These cells are the major 
source of the excessive extracellular matrix production that characterizes fibrotic liver (Viera 
and Nato, 2006). It is possible that eEF1A-1 may play a role in the progression to fibrosis 
during the process of hepatic stellate cell activation. Future experiments in which expression 
of eEF1A-1 in hepatic stellate cells is reduced in obese mice may give us further insight into 
the role this protein plays in the progression of NAFLD.  
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APPENDIX A 
Animal Use Protocols 
 
  
 The University of Western Ontario 
Animal Use Subcommittee / University Council on Animal Care 
Health Sciences Centre, ● London, Ontario ● CANADA – N6A 5C1 
PH: 519-661-2111 ext. 86770 ● FL 519-661-2028 ● www.uwo.ca / animal 
 
           
February 18, 2010 
 
     *This is the Original Approval for this protocol* 
*A Full Protocol submission will be required in 2014* 
 
Dear Dr.  Borradaile: 
 
Your Animal Use Protocol form entitled: 
Liver Function During Obesity and Type 2 Diabetes 
Funding Agency  Canadian Lipoprotein Conference 
 
has been approved by the University Council on Animal Care. This approval is valid from February 18, 2010 to 
February 28, 2011.  The protocol number for this project is 2010-018. 
 
1.  This number must be indicated when ordering animals for this project. 
2.  Animals for other projects may not be ordered under this number. 
3.  If no number appears please contact this office when grant approval is received. 
     If the application for funding is not successful and you wish to proceed with the project, request that an internal 
scientific peer review be performed by the Animal Use Subcommittee office. 
4.  Purchases of animals other than through this system must be cleared through the ACVS office.  Health 
certificates will be required. 
 
ANIMALS APPROVED FOR 4 Years   
Species 
4 Year Total 
Numbers 
Estimated as 
Required 
List All Strain(s) Age / Weight  
Mouse 240 C57Bl/6/  ob/ob 4-5 weeks 
 
 
 
 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar 
with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components 
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and 
have received all necessary approvals.  Please consult directly with your institutional safety officers. 
 
 
 
c.c.  Approval - N. Borradiale, W. Lagerwerf 
         
 
 
AUP Number: 2011-044 
PI Name: Borradaile, Nica M 
AUP Title: Vascular Regeneration After Increased Nad+ Availability In Diet Induced Metabolic 
Syndrome 
 
Approval Date: 03/09/2012 
Review Date: 03/09/2013 
Expiry Date: 03/09/2016 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use Protocol 
(AUP) entitled "Vascular Regeneration After Increased Nad+ Availability In Diet Induced Metabolic 
Syndrome" has been APPROVED by the Animal Use Subcommittee of the University Council on 
Animal Care. This approval, although valid for four years, and is subject to annual Protocol 
Renewal.2011-044::1 
1. This AUP number must be indicated when ordering animals for this project.  
2. Animals for other projects may not be ordered under this AUP number.  
3. Purchases of animals other than through this system must be cleared through the ACVS 
office. Health certificates will be required.  
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety 
standards and have received all necessary approvals. Please consult directly with your institutional 
safety officers. 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
University Council on Animal Care  
 
Page 1 of 1
09/03/2012file://C:\Documents and Settings\nborrad\Local Settings\Temp\XPgrpwise\4F59F08FMe...
2010-018::3:
AUP Number: 2010-018
AUP Title: Liver function during obesity and type 2 diabetes
Yearly Renewal Date: 03/01/2013
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-018 has been approved, and 
will be approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the ACVS 
office.
Health certificates will be required. 
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in 
this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D 
on behalf of the Animal Use Subcommittee 
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